在血浆或血清蛋白质组中鉴定生物标志物候选物。

Identifying Biomarker Candidates in the Blood Plasma or Serum Proteome.

作者信息

Garcia Sheila, Silva-Costa Licia C, Reis-de-Oliveira Guilherme, Guest Paul C, Baldasso Paulo A, Cassoli Juliana S, Martins-de-Souza Daniel

机构信息

Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Rua Monteiro Lobato, 255, 13083-862, Campinas, SP, Brazil.

UNICAMP's Neurobiology Center, Campinas, Brazil.

出版信息

Adv Exp Med Biol. 2017;974:193-203. doi: 10.1007/978-3-319-52479-5_15.

DOI:10.1007/978-3-319-52479-5_15

PMID:28353236

Abstract

Brain disorders are among the most complex and difficult to understand of human disorders in terms of pathophysiology and etiology. Differently from other human diseases such as cancer, which uses biomarkers in clinical practice, there are no prognostic and diagnostic biomarkers available for psychiatric disorders. Those associated with the likelihood of a successful medication are also not existent, impairing treatment strategies. Proteomics is a suitable tool for identifying such biomarkers to be validated and further implemented in the clinic. Here we present a protocol for the proteome analyses of blood plasma and serum collected in vivo, aiming for the discovery of potential biomarkers and the comprehension of the molecular bases of diseases and treatments.

摘要

就病理生理学和病因学而言，脑部疾病是人类疾病中最复杂且最难理解的疾病之一。与癌症等其他人类疾病不同，癌症在临床实践中使用生物标志物，而精神疾病尚无可用的预后和诊断生物标志物。与药物治疗成功可能性相关的生物标志物也不存在，这损害了治疗策略。蛋白质组学是识别此类有待在临床中验证并进一步应用的生物标志物的合适工具。在此，我们提出了一种用于体内采集的血浆和血清蛋白质组分析的方案，旨在发现潜在的生物标志物，并理解疾病和治疗的分子基础。